Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 658 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically... April 30, 2025 Wine Racks and the Mystery of Survival September 16, 2022 What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 Load more HOT NEWS The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... Three Women Running the Length of Michigan to Raise Funds for... FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment...
